MS-N184 · Digital mind–body support · Appraised October 30, 2026

Virtual-reality mindfulness during chemotherapy

Aliases: VR-supported mindfulness

Evidence at a glance

Question: Is virtual-reality mindfulness practical and acceptable during outpatient chemotherapy?
Finding: A three-arm randomized feasibility study enrolled only 85 of 1,590 formally eligible people. VR mindfulness was feasible but required substantial staff support, had frequent disruptions and was not more acceptable than receptive music.
Evidence label: Feasibility only; no efficacy conclusion
Benefit: The study does not establish symptom benefit.
Certainty: Low for effectiveness because efficacy was not the study objective; useful implementation evidence for real-world burden.
Risk: Participants generally rated the intervention positively, but the authors noted it may feel overwhelming during infusion. Systematic adverse-event results were not reported.
Cancer-control boundary: This was an implementation study, not evidence of cancer control or improved chemotherapy outcomes.

Study details

Intervention: VR-supported mindfulness delivered during two consecutive outpatient chemotherapy sessions.
Comparators: Receptive music during infusion and a control group.
Design and sample: Single-center three-arm randomized feasibility study; 3,072 approached, 1,590 formally eligible and 85 enrolled, a 5.4% participation rate.
Primary focus: Feasibility and acceptability, assessed through recruitment, structured observation and a post-intervention questionnaire.
Results: Both VR mindfulness and music were feasible. VR needed considerable personnel support, disruptions were common and acceptability was not higher than music.
Negative findings: Low uptake and no acceptability advantage over the simpler music intervention.
Limitations: Not powered or designed for efficacy; two-session exposure; one center; German-language report; safety and symptom-effect estimates not verified.
Funding and conflicts: Funding was not reported in the PubMed record; authors declared no conflicts.

Practical safety context

VR can aggravate motion sensitivity, headache, dizziness, visual discomfort or infusion-related nausea. It should never obstruct monitoring, communication, venous access or prompt reporting of infusion reactions.

Questions for the care team

Could headphones or a simple audio exercise deliver the same practical value?
Will VR interfere with clinical observation or worsen nausea or dizziness?
Is the goal acceptability, immediate distress relief or a durable symptom change?

Primary sources

Last literature search: October 30, 2026 · Record appraisal: October 30, 2026

Educational evidence summary, not medical advice. Do not change cancer treatment or supportive medications without discussing the decision with the treating team.